Zofran Lawsuit Study Indicates Twofold Increase In Cleft Palate For Infants Exposed To Drug

January 14, 2016 – – ZofranLegal.com reports on the findings of multiple studies which appear to link Zofran to the development of congenital birth defects in fetuses when they are are exposed to the drug through their mothers while developing in utero. The drug was developed by pharmaceutical giant GlaxoSmithKline, and marketed “off-label” to pregnant women across the nation.

Zofran is an anti-nausea medication which gained approval by the United States Food and Drug Administration to treat patients experiencing nausea and vomiting after undergoing chemotherapy, radiation therapy, or anesthesia. After this specific approval, however, GlaxoSmithKline also marketed their drug as a morning sickness treatment to Ob/Gyn offices and the general public. Plaintiffs in lawsuits involving the drug today say that this was reckless and negligent given the fact that the drug had never been FDA approved for this use, or tested for safety on this consumer group.

Today, Zofran is the subject of a surge of lawsuits from parents around the U.S. which commonly allege when pregnant mothers take the drug, they are putting their growing babies at increased risk for the development of severe or even fatal congenital defects. Defects noted in the many lawsuits which have been filed most commonly link Zofran exposure to cleft lip and palate, kidney defects, clubfoot, transposition of the greater vessels, atrial septal defect and ventricular septal defect, tetralogy of fallot, and respiratory distress. Defects which do not prove fatal have generally required multiple dangerous corrective surgeries.

Plaintiffs involved in Zofran birth defect lawsuits have several studies on their side. A 2012 study highlighted a twofold increase in the risk of cleft palate for fetuses exposed to Zofran while developing in utero. Another study, which was published in 2014, found that Zofran exposure appeared to cause a 30% overall increased risk for congenital malformations in developing fetuses.

The mounting Zofran lawsuits have been consolidated to form multidistrict litigation number 2657 by the U.S. Judicial Panel on Multidistrict Litigation. This will help to fast track the litigation process, avoiding duplicate discovery and different rulings from multiple judges. Additionally, it helps to conserve resources for everyone involved. The consolidated cases are being overseen by Judge F. Dennis Saylor IV in Boston, Massachusetts.

As the cases await further preparations for trial, the attorneys at Monheit Law are working to ensure that everyone who used Zofran while pregnant and later gave birth to a child with defects will have the opportunity to explore their legal rights. These mothers and their families may be entitled to significant compensation. At this time, Monheit Law is offering free legal consultations to qualified individuals.

To ask questions or request further information, contact Michael Monheit, Esq., lead attorney at Monheit Law by calling (877) 620-8411.

###

Contact ZofranLegal.com:

Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046

ReleaseID: 60007229